The American drug agency (FDA) has given the green light to the authorization of a treatment against hemophilia, indicated Thursday evening the French laboratory Sanofi, which is developing it with the Swedish biotech Sobi.
The treatment, ALTUVIIIO (previously referred to as “
efanesoctocog alpha
”) is indicated for routine prophylaxis and on-the-spot treatment to control bleeding episodes, as well as for surgical management in adults and children with hemophilia A, specifies Sanofi in its press release.
It is taken in a weekly dose.
Read alsoHow Sanofi operates in Ukraine
Hemophilia A is a rare and dangerous bleeding disorder, which overwhelmingly affects boys.
It results in the inability of blood to clot properly due to a deficiency in clotting factor.
It causes excessive and spontaneous bleeding in the joints, causing lesions and chronic pain and which can have important repercussions on the quality of life.
Sanofi had obtained last June the designation of “
innovative treatment
” in the United States for this molecule.
The FDA also granted it orphan drug designation in August 2017.
